Agreement Reached Between Senseonics and Ascensia Diabetes Care for Control of Commercialization and Distribution of Eversense 365

Senseonics Holdings, Inc., a medical technology company specialising in long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, has shared its financial expectations for the year 2025 and announced a significant transition in its business structure.

The company anticipates its full-year 2025 global net revenue to be approximately $34-38 million. According to Senseonics, about one-third of this revenue is expected to be generated in the first half of 2025, with the remaining two-thirds in the second half.

In a move aimed at accelerating growth and realising the full potential of Eversense, Senseonics plans to unify the Eversense business and incorporate commercial activities directly within the company. This transition is set to begin on January 1, 2026, with Senseonics assuming responsibility for all global sales, marketing, and commercialization in the U.S.

The transition is accompanied by strategic appointments. Brian Hansen, currently President of CGM at Ascensia since February 2024 and former Chief Commercial Officer at Tandem Diabetes Care, will join Senseonics as Chief Commercial Officer on January 1, 2026.

Senseonics expects to see immediate revenue improvement and gross margin expansion in 2026. The company aims for gross margins to expand to 50% in 2026, with a planned increase to more than 70% gross margins at scale. To fund the commercial organization, Senseonics has expanded a non-dilutive debt facility up to $100 million with Hercules Capital.

The company also announced a Memorandum of Understanding to transition all commercialization and distribution of Eversense 365 and future products from Ascensia Diabetes Care. Eversense 365, the world's first and only year-long continuous glucose monitor, is a testament to Senseonics' commitment to innovation in diabetes care.

Management will host an investor call and live webcast on September 4, 2025, at 8:00 A.M. Eastern Time to discuss these developments further. The link to the webcast will be available on Senseonics Holdings, Inc. website at www.senseonics.com. To listen to the conference call, please dial 1-800-579-2543 (US/Canada) or 1-785-424-1789 (International), passcode SENSE365.

Cash used in operations in 2025 is expected to be approximately $60 million. Senseonics has also expanded a credit facility of up to $100 million in 2025 to finance its commercial organization, although the specific bank involved remains undisclosed in the available search results.

The company anticipates doubling its global patient base during 2025. Second half revenue is expected to be weighted to the fourth quarter due to a one-time shift to once-a-year Eversense 365 reorder dynamics. Gross margins are expected to increase throughout 2025, with 2025 gross margins between 32.5% and 37.5% for the full year.

This strategic transition and financial outlook mark an exciting period for Senseonics as it continues to pioneer in the field of long-term CGM systems for people with diabetes.